devoted to determining and implementing the best ways
to prevent, diagnose and treat diseases in children
in an independent global collaboration that seeks to standardize
best practices across disease areas and populations
such as flexibility, commitment and transparency
to generate the scientific data necessary to market drugs
at doses that are safe and effective for children
so as to harness the body's response
to HIV and antiretrovirals
to ensure effective treatments are available
for common infections for generations to come
to make powerful informed decisions about their health
and healthcare and improve the quality of their lives
The ODYSSEY trial’s final paper Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children has been published in the New England Journal of Medicine. ODYSSEY, sponsored by Penta and funded by ViiV Healthcare, is the first randomised controlled trial to compare the efficacy and safety of dolutegravir-based regimens to non-dolutegravir-based standard-of-care regimens in…READ MORE
Penta youth in collaboration with IAS, have organised a webinar taking place on Thursday, 16 December at 12pm CET (GMT+1) on the theme Invest in our future: How to walk the talk of ethical Youth engagement in the HIV response. The objectives of the webinar are to showcase best practices for youth participation within the…READ MORE
Through independent research into child health, Penta is one of the most prominent scientific organizations dedicated to children’s health.
We are an alliance of people united by a common purpose: to improve prevention, diagnosis and treatment of infection in children.
Our global independent scientific network brings together key stakeholders in paediatric infectious disease, including researchers, clinicians, regulatory bodies, the pharmaceutical industry and patients and their families, to develop and deliver world class research and training to drive contemporary understanding and practice related to infections in children.
We are involved in research projects globally that operate along the scientific priorities: HIV & viral infection, severe sepsis and antimicrobial resistance, infection in pregnancy and neglected or emerging childhood infections. We do not just carry out clinical trials, but cohort studies collaboration and pregnancy studies.
Our research embraces basic, pharmacological, clinical, social and population sciences.
Our operational model is based on networking, independence, transparency and commitment.
We continue to build on our existing partnerships and seek out potential new collaborations to further our work.
The Penta ID Network continues to grow, bringing together patients and their care-givers worldwide to address a wide range of healthcare issues.
